Loading...
•
Mar 31, 2023
Chemours Q1 2023 Earnings Report
Chemours' first quarter was marked by growth in TSS and APM segments, with record results in TSS driven by Opteon demand. The company reaffirmed its full-year Adjusted EBITDA and Free Cash Flow guidance.
Key Takeaways
Chemours reported Net Sales of $1.5 billion, Net Income of $145 million, and Adjusted EBITDA of $304 million for Q1 2023. The company experienced strong performance in its Thermal & Specialized Solutions (TSS) segment, driven by demand for OpteonTM solutions, while the Titanium Technologies (TT) segment faced challenges due to lower demand.
Net Sales reached $1.5 billion, with Net Income at $145 million and EPS of $0.96.
Adjusted Net Income was $148 million, with Adjusted EPS at $0.98.
Adjusted EBITDA stood at $304 million.
Thermal & Specialized Solutions (TSS) achieved record first-quarter results, driven by strong pricing and demand for OpteonTM solutions.
Chemours
Chemours
Forward Guidance
The Company is reaffirming its full year 2023 Adjusted EBITDA and Free Cash Flow guidance. The Company expects full year 2023 Adjusted EBITDA to be within the range of $1.20 - $1.30 billion and expects Free Cash Flow of greater than $350 million, inclusive of approximately $400 million of capital expenditures.
Positive Outlook
- The Company is reaffirming its full year 2023 Adjusted EBITDA guidance.
- The Company is reaffirming its full year 2023 Free Cash Flow guidance.
- The Company expects full year 2023 Adjusted EBITDA to be within the range of $1.20 - $1.30 billion
- The company expects Free Cash Flow of greater than $350 million
- Guidance is inclusive of approximately $400 million of capital expenditures.